Further Study Supporting NEO 100's Ability To Safely Deliver Therapeutics Through The Blood Brain Barrier
NEO100 enables brain delivery of blood-brain barrier impermeable therapeutics.
Authors: Weijun Wang1, Nagore I. Marín-Ramos1, Haiping He1,2, Shan Zeng1,2, Hee-Yeon Cho1, Stephen D. Swenson1, Long Zheng3, Alan L. Epstein3, Axel H. Schönthal4, Florence M. Hofman3, Ligang Chen2 and Thomas C. Chen1,4
A new study conducted by NeOnc Technologies into the efficacy of its NEO 100 formulation to safely deliver therapeutics to the brain through the Blood-Brain Barrier was concluded in August of 2020. This study was done to specifically study not only the ability to permeate the BBB but also the impact such migration would have on the area of transfer. The maintenance of BBB integrity is essential for CNS homeostasis so it is critical that any attempt to permeate the BBB be reversible and non-damaging to the tissue. This study showed that NEO100 transiently and reversibly permeabilizes the BBB at subcytotoxic doses thereby safely delivering to the brain with no damage to the BBB.
NEO100 opened the BBB in a reversible and nontoxic fashion in vitro and in vivo. It enabled greatly increased brain entry of all tested therapeutics and was well tolerated by animals. Mechanistic studies revealed the effects of NEO100 on different BBB transport pathways, along with translocation of tight junction proteins from the membrane to the cytoplasm in brain endothelial cells.